Nachrichten zur Bristol-Myers Squibb Co. Aktie

Is Bristol Myers Squibb Stock a Buy?

The company is going through a rough patch.…

[Latest] Global PARP Inhibitors Market Size/Share Worth USD 23.5 Billion by 2032 at a 12.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global…

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Squibb Company - BMY

NEW YORK, March 23, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…

Bristol-Myers Squibb Is Not A Buy For Me

…

Bristol Myers Squibb completes Karuna Therapeutics buyout By Investing.com

Bristol Myers Squibb completes Karuna Therapeutics buyout…

Bristol-Myers Squibb Company (BMY) Barclays 26th Annual Global Healthcare Conference (Transcript)

…

Karuna Therapeutics set to merge with Bristol-Myers Squibb By Investing.com

Karuna Therapeutics set to merge with Bristol-Myers Squibb…

Bristol-Myers Squibb: Großes Interesse an ADC-Playern - Tubulis holt hochkarätige Investoren an Bord - Aktienanalyse

Kulmbach (www.aktiencheck.de) - Bristol-Myers Squibb-Aktienanalyse von "Der Aktionär": Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt die Aktie von Bristol-Myers Squibb Company…

Bristol-Myers Squibb Company (BMY) Management Presents at Leerink Partners Global Biopharma Conference 2024 Conference (Transcript)

…

Bristol Myers, Moderna und Roche ziehen Anti Virus-Index auf Jahreshoch

Der Global Anti Virus Health Net Return Index hat in den zurückliegenden Tagen von der Mehrheit der Indexmitglieder Rückenwind erhalten.…

Societe Generale cuts Bristol-Myers Squibb to Hold By Investing.com

Societe Generale cuts Bristol-Myers Squibb to Hold…

Bristol-Myers Squibb: Finally Trending Up

…

Chemotherapy Induced Peripheral Neuropathy Treatment Global Market Report 2024, Featuring Sanofi, Bristol Myers Squibb, Abbott Laboratories, Takeda Pharmaceutical and Amgen

Dublin, March 08, 2024 (GLOBE NEWSWIRE) -- The "Chemotherapy Induced Peripheral Neuropathy Treatment Global Market Report 2024" has…

Bristol-Myers Squibb: Turnaround Expected

…

Bristol-Myers Squibb: Compelling Value From The New Products Portfolio And 4.5% Yield

…

Bristol-Myers Squibb Company (BMY) 44th Annual TD Cowen Healthcare Conference (Transcript)

…

Follicular Lymphoma Market to Witness Upsurge in Growth by 2032, Predicts DelveInsight | Key Companies - AbbVie, Genmab, Novartis, Allogene Therapeutics, Pfizer, Genentech, Incyte Corporation, Bristol-Myers Squibb

The dynamics of the follicular lymphoma market are anticipated to change in the coming years owing to the improvement in…

Bristol Myers Squibb completes RayzeBio acquisition By Investing.com

Bristol Myers Squibb completes RayzeBio acquisition…

Bristol Myers Squibb nears RayzeBio acquisition completion By Investing.com

Bristol Myers Squibb nears RayzeBio acquisition completion…

This $674 Million Deal Aims To Turn Your Bodys Garbage Disposal Into A Disease Fighter

VantAI has inked a partnership with pharma giant Bristol Myers Squibb that hopes to use the body’s cellular waste disposal…

How This Top 2% Biotech Overcame Two Obstacles And Doubled

Cytokinetics is looking to take on Bristol Myers Squibb in treating a heart disease.…

Senators to question Merck, J&J and Bristol Myers Squibb CEOs over high U.S. drug pricing

The push to cut drug prices is one of those rare hot-button issues that unites the two major political parties.…

Redburn cuts Bristol-Myers Squibb price target to $54 By Investing.com

Redburn cuts Bristol-Myers Squibb price target to $54…

FDA to review expanded use of Bristol Myers Squibbs Abecma By Investing.com

FDA to review expanded use of Bristol Myers Squibbs Abecma…

Bristol-Myers Squibb: All Focus On Execution

…

Bristol-Myers Squibb: Massive Discount Spells Opportunity

…

Bristol Myers Squibb (BMY) Q4 2023 Earnings Call Transcript

BMY earnings call for the period ending December 31, 2023.…

Bristol-Myers Squibb Company 2023 Q4 - Results - Earnings Call Presentation

…

Bristol-Myers Squibb Company (BMY) Q4 2023 Earnings Call Transcript

…

Bristol Meyers Squibb, AbbVie top 4Q sales and profit estimates

Drugmakers Bristol-Myers Squibb Co (NYSE:BMY, ETR:RM, OTC:BMYMP) and Abbvie Inc (NYSE:ABBV) on Friday both reported better than expected financial results...…

Stocks making the biggest premarket moves: Meta, Amazon, Bristol-Myers Squibb, Chevron and more

These are the stocks posting the largest moves in the premarket.…

Bristol-Myers Squibb beats in Q4 as Eliquis and Opdivo outperform

…

Bristol-Myers Squibb tops Q4 expectations, reports strong anemia drug sales By Investing.com

Bristol-Myers Squibb tops Q4 expectations, reports strong anemia drug sales…

Bristol-Myers Squibb earnings beat by $0.10, revenue topped estimates By Investing.com

Bristol-Myers Squibb earnings beat by $0.10, revenue topped estimates…

Bristol Myers Squibb results top expectations as newer drugs help fuel growth

Bristol Myers Squibb on Friday reported fourth-quarter results that beat analysts’ expectations, helped by portfolio stalwarts as well as newer…

Bristol Myers Squibb results top estimates as new drugs post strong sales growth

Bristol Myers Squibb also issued its full-year 2024 forecast, which was generally in line with expectations.…

Antibiotics Market revenue to surpass USD 108 Billion by 2035, says Research Nester

Major antibiotics market players include F.Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Teva Pharmaceuticals Industries Ltd., Pfizer Inc., Abbott Laboratories, Merck…

Bayer und Eli Lilly: Heißer Markt

Der Markt für Radiopharmaka bleibt für große Player von Interesse. Das haben die jüngsten Übernahmen von Rayzebio (durch Bristol Myers…

Healthy Returns: J&J, Merck and Bristol Myers Squibb are in the hot seat

J&J, Merck and Bristol Myers Squibb face a pivotal few weeks ahead. Meanwhile, Apple will reportedly explore health applications for…

Merck, Johnson & Johnson CEOs agree to testify in Senate hearing on high drug prices

The CEOs of Merck, Johnson & Johnson and Bristol Myers Squibb will testify at the hearing on drug prices, Sen.…

Bristol-Myers Squibb: Dont Waver Over Undue Fears And Doubts

…

Is Bristol Myers Squibb Stock a Buy Now?

This healthcare stock has seen healthier days.…

Melanoma Drugs - $13.98 Billion Industry Opportunity Assessment, 2024-2028: Regional Insights and Competitor Market Shares

Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Melanoma Drugs Global Market Report 2024" report has been added…

dpa-AFX ProFeed